Streamlining Gastroenterology Prior Authorization with Da Vinci PAS

Klivira streamlines **gastroenterology Da Vinci PAS** workflows, automating prior authorization for high-volume GI biologics, procedures, and advanced imaging.

Revenue cycle leaders and prior authorization coordinators in gastroenterology face a complex, high-volume PA landscape, particularly for chronic conditions like IBD and diagnostic procedures. Manual processes, unstructured documentation, and varied payer requirements lead to delays and denials. Implementing Da Vinci PAS offers a standardized, FHIR-native approach to mitigate these challenges, enhancing efficiency and improving patient access to critical GI care.

The Gastroenterology Prior Authorization Landscape

Gastroenterology practices navigate a demanding prior authorization environment, particularly for high-cost biologics, advanced diagnostic imaging, and complex endoscopic procedures. Conditions such as Inflammatory Bowel Disease (IBD) and Hepatitis C often require chronic treatment and rigorous documentation, leading to recurrent PA submissions. The variability in payer policies for step therapy, biosimilar mandates, and disease severity criteria further complicates timely care delivery.

Key PA Triggers in Gastroenterology

**IBD Biologics**: TNF inhibitors (adalimumab, infliximab), integrin inhibitors (vedolizumab), IL-12/23 inhibitors (ustekinumab), JAK inhibitors (tofacitinib, upadacitinib), S1P modulators (ozanimod, etrasimod), risankizumab.
**Hepatitis C DAAs**: sofosbuvir-velpatasvir, glecaprevir-pibrentasvir, with specific pathways for treatment-naive vs. experienced patients.
**Advanced Imaging**: MRCP, MR enterography, CT enterography for IBD assessment and other abdominal conditions.
**Endoscopic Procedures**: Capsule endoscopy (CPT 91110), small-bowel enteroscopy, ERCP, and EUS for diagnostic and therapeutic indications.
**Specialty Functional GI Drugs**: eluxadoline, prucalopride, linaclotide, plecanatide for IBS-D, chronic constipation, and IBS-C/CIC.
**Non-routine Colonoscopy**: Surveillance colonoscopies following polyp removal or for high-risk patients.

Leveraging Da Vinci PAS for GI Workflows

The HL7 Da Vinci Project's Prior Authorization Support (PAS) Implementation Guide, built on HL7 FHIR R4, offers a standardized pathway to automate and streamline prior authorization. For gastroenterology, this means moving beyond fragmented payer portals and fax-based submissions to a structured, data-driven exchange. Klivira's Da Vinci PAS implementation integrates with EMRs to facilitate coverage requirements discovery via Da Vinci CRD, structured documentation assembly via Da Vinci DTR, and direct submission to payer PAS endpoints, significantly reducing administrative burden.

Klivira's Da Vinci PAS Workflow for GI

**CRD at Order Entry**: Klivira's CDS-Hook integration identifies PA requirements for GI biologics, procedures, or imaging orders directly within the EMR.
**DTR-Driven Documentation**: Payer-specific DTR questionnaires are presented, auto-populating clinical data from the EMR (e.g., Mayo score, genotype, fibrosis stage) for IBD or Hep C.
**Standardized PAS Submission**: Assembled FHIR `Claim` resources, including structured clinical documentation, are submitted to the payer's PAS endpoint via the `$submit` operation.
**Synchronous/Asynchronous Response**: Klivira parses the `ClaimResponse` into a consistent workflow state, tracking approvals, denials, or pending statuses for GI-specific cases.
**EMR Write-Back**: Authorization numbers and decision details are written back to the EMR's order record, providing a closed-loop workflow for GI care.
**X12 278/275 Fallback**: Klivira intelligently routes to X12 278/275 or portal submission for payers not yet fully PAS-conformant, ensuring continuity.

Addressing GI-Specific Documentation and Denial Challenges

Klivira's platform, leveraging Da Vinci PAS, directly confronts common GI prior authorization hurdles. It automates the verification of step therapy compliance for IBD biologics, ensures documentation of disease severity (e.g., Mayo score, CDAI) and crucial screenings (e.g., TB, hepatitis pre-biologic), and manages the complexities of treatment-naive vs. treatment-experienced classifications for Hep C DAAs. By adhering to guidelines from bodies like ACG, AGA, and AASLD, Klivira helps mitigate denials stemming from incomplete or misaligned clinical information.

Benefits of Standardized GI PA with Klivira

**Reduced Administrative Burden**: Automate manual tasks associated with chronic-treatment re-authorizations and complex documentation.
**Improved Decision Turnaround**: Structured FHIR data enables faster payer-side review, accelerating access to critical GI medications and procedures.
**Higher First-Pass Approval Rates**: Ensure all required clinical documentation, aligned with ACG/AGA guidelines and payer policies, is submitted accurately.
**Enhanced EMR Integration**: Seamlessly integrate PA workflows into existing EMR systems, minimizing staff disruption.
**Future-Proof Compliance**: Align with emerging mandates like CMS-0057-F, preparing for the 2027 Prior Authorization API requirement for impacted payers.
**Optimized Resource Allocation**: Free up PA coordinators to focus on complex cases requiring clinical judgment, rather than data entry.

Frequently asked questions

How does Da Vinci PAS specifically benefit prior authorizations for IBD biologics in gastroenterology?

Da Vinci PAS standardizes the submission of complex clinical data required for IBD biologics, such as disease severity scores (Mayo score, CDAI), prior therapy trials, and screening results. Klivira's implementation uses Da Vinci DTR to guide structured documentation, reducing common denial reasons related to missing or unstructured information, and supports periodic re-authorization workflows.

Can Da Vinci PAS streamline the documentation for advanced GI imaging or endoscopic procedures?

Yes, Da Vinci PAS, particularly through its Documentation Templates and Rules (DTR) component, can guide the capture of specific clinical rationale and prior workup details for advanced GI imaging (e.g., MR enterography) and endoscopic procedures (e.g., capsule endoscopy). This ensures that medical necessity criteria, often a source of denials, are explicitly addressed with structured data.

How does Klivira handle the medical vs. pharmacy benefit split for GI biologics within a Da Vinci PAS framework?

Klivira's platform is designed to identify and route GI biologic prior authorizations correctly based on the mode of administration and associated benefit. While Da Vinci PAS focuses on the data exchange standard, Klivira's internal logic distinguishes between medical benefit (provider-administered infusions) and pharmacy benefit (self-administered injections), ensuring the appropriate PA pathway is followed for the same agent and patient.

What role do clinical guidelines like ACG or AGA play in Klivira's Da Vinci PAS implementation for GI?

Klivira integrates knowledge of clinical guidelines from bodies such as ACG (American College of Gastroenterology), AGA (American Gastroenterological Association), and AASLD (American Association for the Study of Liver Diseases) into its PA logic. This allows the platform to guide users in providing documentation that aligns with evidence-based criteria, supporting step therapy compliance and medical necessity for GI treatments within the Da Vinci PAS framework.

How does Klivira ensure compliance with CMS-0057-F requirements for GI prior authorizations?

Klivira tracks payer conformance with CMS-0057-F, which mandates FHIR-based Prior Authorization APIs by January 1, 2027, for specific payer types. Klivira's Da Vinci PAS implementation aligns with these FHIR API requirements, enabling gastroenterology practices to meet the evolving regulatory landscape, including the expected 72-hour standard and 24-hour expedited decision timeframes for impacted payers.